Vicky Makker
维基·马克尔
MD, MHA
Associate Attending Physician, Gynecologic Medical Oncology Service妇科内科肿瘤科副主治医师
👥Biography 个人简介
Dr. Vicky Makker at MSKCC is a leading expert in endometrial cancer, best known for developing the lenvatinib plus pembrolizumab combination regimen. Her KEYNOTE-146/Study 111 work led to FDA approval of this combination in advanced endometrial cancer, transforming second-line treatment.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Lenvatinib-Pembrolizumab Combination
Led KEYNOTE-146 trial establishing lenvatinib plus pembrolizumab in advanced endometrial cancer, achieving FDA approval and becoming a new standard of care in second-line therapy.
Endometrial Cancer Biomarker Research
Advanced understanding of predictive biomarkers for immunotherapy response in endometrial cancer, including TMB and mismatch repair status in treatment selection.
Representative Works 代表性著作
Lenvatinib plus Pembrolizumab in Advanced Endometrial Cancer (KEYNOTE-146)
Journal of Clinical Oncology (2020)
Established lenvatinib-pembrolizumab combination efficacy leading to accelerated FDA approval in advanced endometrial cancer.
Lenvatinib plus Pembrolizumab vs Chemotherapy in Advanced Endometrial Cancer (Study 309/KEYNOTE-775)
New England Journal of Medicine (2022)
Confirmed OS and PFS benefit of lenvatinib-pembrolizumab over chemotherapy in previously treated endometrial cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Bradley J. Monk
University of Arizona / HonorHealth
Kathleen N. Moore
Stephenson Cancer Center, University of Oklahoma
Ana Oaknin
Vall d'Hebron University Hospital
Shannon Neville Westin
The University of Texas MD Anderson Cancer Center
关注 维基·马克尔 的研究动态
Follow Vicky Makker's research updates
留下邮箱，当我们发布与 Vicky Makker（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment